Seeking evidence that macrolides may be effective in subgroups of patients with neutrophil-mediated lung disease, and that macrolides may slow the progression of COPD by reducing elastin degradation, we conducted a post hoc analysis of the COLUMBUS trial participants. Serum samples had been obtained at baseline ( prior to macrolide treatment) and at 12 months (end of study).
Total serum desmosine (sDES) concentration was measured using a liquid chromatography with mass spectrometry method [2] . Our exploratory objectives were: 1) to determine if baseline sDES predicted response to azithromycin in terms of exacerbation reduction; and 2) to determine if azithromycin treatment resulted in a reduction in sDES from baseline compared to placebo. Finally, in a subgroup of patients, we measured whether sDES changed at onset of acute exacerbation.
A priori, we determined that we would split patients into two groups based on sDES levels above and below the median level in the population (0.39 ng·mL −1 ). This included n=46 for >0.39 ng·mL −1 (n=26 azithromycin-treated, n=20 placebo) and n=45 for <0.39 ng·mL −1 (n=21 azithromycin-treated, n=24 placebo). As has been previously reported, sDES was strongly correlated with age (r=0.53, p<0.0001). Inhaled corticosteroid dose was not different between the two groups ( p=0.7).
We chose to split exacerbations into moderate and severe exacerbations, based on recent data from bronchiectasis suggesting that elevated circulating desmosine was a predictor of severe exacerbations [4] . We analysed frequency of exacerbations using Poisson regression.
The patient characteristics have been previously reported. The mean age was 65 years, patients had a mean of four exacerbations per year at baseline and the mean lung function suggested severe airflow obstruction. Patients were commenced on azithromycin or placebo at baseline, while clinically stable and free from exacerbation, as previously described [11] .
The median level of sDES was 0.39 ng·mL −1 (interquartile range (IQR) 0.25-0.51 ng·mL
). sDES was similar at baseline between azithromycin and placebo groups (median (IQR) 40 (28-51) versus 37 (24-54) ng·mL
, respectively; p=0.5).
In the first analysis of whether sDES could predict macrolide response, there was a significant reduction in the frequency of exacerbations (incident rate ratio ( In those with the lower sDES levels, there was no significant reduction in the frequency of exacerbations (IRR 0.74, 95% CI 0.51-1.07), moderate exacerbations (IRR 0.63, 95% CI 0.40-1.00), time to first exacerbation (HR 0.58, 95% CI 0.31-1.10) or severe exacerbations (IRR 1.02, 95% CI 0.53-1.96).
Exploratory tests of interaction between these groups were statistically nonsignificant, but this was to be expected with this sample size (interaction for total exacerbations −1.26, p=0.1; severe exacerbations −1.16, p=0.1; time to first exacerbation −1.00, p=0.1).
The apparent difference in response was not driven by desmosine enriching for frequently exacerbating patients in the high-desmosine group, as baseline desmosine did not correlate with risk of exacerbations We conclude that azithromycin treatment does not have an impact upon elastin degradation in patients with COPD, but that patients with higher levels of sDES may have a greater response to azithromycin treatment when compared to patients with lower sDES, in terms of reducing exacerbations. This study was exploratory and should be regarded as hypothesis-generating, as the COLUMBUS study was not designed to test for biomarkers of azithromycin response [11] . We observed that sDES did not change during acute exacerbations of COPD and that sDES was not a predictor of future risk of exacerbations or time to first exacerbation. This study is among the first to seek biologically relevant determinants of macrolide response in COPD. Several studies have now shown the value of macrolides to reduce exacerbations in patients with COPD [11] [12] [13] [14] . Clinical predictors of macrolide response were sought by HAN et al. [14] , who examined data from a trial in the USA of 1142 patients with COPD treated with azithromycin 250 mg daily or placebo. They found few clinical predictors of macrolide response, with no difference in response detected by lung function, sex, presence of chronic bronchitis or prior therapy. Interestingly, only current smoking and age >65 years were associated with improved response. sDES and other biological markers were not measured in the study [14] .
Our study also adds to the available data regarding sDES as a biomarker of COPD. Previous studies in the ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points) cohort and other large cohorts found associations between desmosine and age, coronary artery calcification, Medical Research Council dyspnoea score and airflow obstruction, but did not demonstrate a link with emphysema or emphysema progression. Desmosine nevertheless was an independent predictor of mortality in 1177 COPD patients [1, 15] .
In summary, we show that azithromycin use does not reduce sDES over 12 months, but patients with higher levels of sDES may be more responsive to azithromycin treatment. This would justify larger studies of sDES to phenotype patients in COPD. 
